Navigation Links
Not all lung cancer patients who could benefit from crizotinib are identified by FDA-approved test
Date:8/28/2012

Break apart a couple worm-like chromosomes and they may reconnect with mismatched tips and tails such is the case of the EML4-ALK fusion gene that creates 2-7 percent of lung cancers. Almost exactly a year ago, the FDA approved the drug crizotinib to treat these ALK+ lung cancer patients, who were likely never smokers. Informed doctors use the test called a FISH assay to check for the EML4-ALK fusion gene, and then if the test is positive, ALK+ patients benefit greatly from crizotinib.

A recent University of Colorado Cancer Center case study published in the Journal of Thoracic Oncology describes the never-before-seen case of a patient who tested negative for EML4-ALK fusion based on the well-defined criteria for FISH assay as approved by FDA, but nevertheless experienced remission after treatment with crizotinib.

"The case implies that not all patients who might benefit from the drug are captured by the FDA-approved FISH assay. Perhaps despite the FDA pairing of crizotinib with FISH, other assays or other criteria for ALK/FISH positivity could be used," says paper co-author, Fred R. Hirsch, MD, PhD, investigator at the CU Cancer Center and professor of medical oncology and pathology at the CU School of Medicine.

In fact, it was by chance that after the patient's negative FISH, Hirsch and colleagues chose to look deeper. Besides using FISH to stain sections of chromosomes with the EML4-ALK fusion gene, the team used immunohistochemistry to look for the protein products of this fusion gene not the faulty plans but the faulty results. Sure enough, in this case, the patient had the EML4-ALK fusion protein but apparently without the typical EML4-ALK fusion gene that should code for it.

The team looked deeper, using next-gen sequencing to discover what, exactly, was going on in the short arm of chromosome number 2, which harbors the EML4-ALK fusion gene. What they found looked less like a pair of clean breaks that reattached in the wrong places say, like a snapped radius and ulna that found the wrong reattachments to make a rulna and an ulnius but more like shattered fragments with genetic shards embedded in and around the primary sections.

"We think these genetic shards made the resulting gene look different enough from the typical EML4-ALK fusion gene to avoid detection by the FDA approved FISH assay," Hirsch says.

Within two weeks of starting crizotinib, the patient reported improved pain symptoms and energy. Four months after starting the drug, a PET scan, which shows the sugar signatures of rapidly developing cancer cells, was negative. A chest CT scan showed the primary tumor had shrunk by 75 percent.

"Certainly FISH is a valuable assay to check for ALK-positive lung cancer," Hirsch says. "But we hope this work demonstrates the need to further refine this test, to ensure that all the patients who could benefit from crizotinib in fact receive the drug."

Together with CU Cancer Center colleagues including Drs. Doebele, Garcia, Aisner and Camidge, Hirsch is participating in a larger study comparing different assays for ALK testing to determine which assay or combination of assays identifies the most patients likely to benefit from crizotinib.


'/>"/>
Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Breast Cancer Drug Might Help Men on Prostate Cancer Therapy
2. Reducing the side effects of treatment for prostate cancer
3. Accuracy of narrow band imaging with colonoscopy allows for distal non-cancerous polyps to be left in place
4. Daily Aspirin May Help Fight Prostate Cancer, But Not Breast Cancer
5. WSU researcher documents links between nutrients, genes and cancer spread
6. Excess Pounds Raise Risk of Breast Cancer Recurrence, Death: Study
7. Johns Hopkins team finds ICU misdiagnoses may account for as many annual deaths as breast cancer
8. Compounds activate key cancer enzyme to interfere with tumor formation
9. Lack of sleep found to be a new risk factor for aggressive breast cancers
10. Cancer vaccine Special Focus series published in Human Vaccines & Immunotherapeutics
11. Obese and overweight women face increased risk of recurrence of most common type of breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Silver Birch ... community, which is located on more than four acres of land at 5620 Sohl ... , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each of ...
(Date:5/26/2017)... Centennial, Colorado (PRWEB) , ... May 26, 2017 ... ... Exchange will be this year’s recipient of proceeds from its 14th Annual Clays ... Club, 46700 E. County Road 30, Bennett, Colorado. , As part of ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... ... and background. Understanind and choosing the most appropriate instruments for research and understanding ... in research finding. This webinar will focus on innovations in stereo microscopy for ...
(Date:5/24/2017)... ... , ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now welcoming ... referral. Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take on ... no longer need to feel the esthetic effects of wires and brackets when they ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... in which the endometrial lining of the uterus spreads into the pelvic ... experiencing painful intercourse, painful periods, pelvic pain, or irregular bleeding may have ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)... , May 17, 2017  Bayer announced today that ... will be presented at the 53 rd Annual ... taking place June 2-6 in Chicago ... ASCO span prostate, colorectal, liver and thyroid cancers, as ... the Phase II CHRONOS-1 trial of copanlisib in patients ...
(Date:5/10/2017)... 2017 Hologic, Inc. (Nasdaq: HOLX ... fiscal second quarter ended April 1, 2017 .   ... 666.7% compared to the prior year period as the ... significant gain, while non-GAAP diluted EPS of $0.50 increased ... in constant currency terms.  Excluding the effects of blood ...
(Date:5/9/2017)... , May 9, 2017 Zimmer Biomet ... in musculoskeletal healthcare, today announced it has earned a ... of 2017" list. The Company was ranked among 500 ... Large Employers and Healthcare Equipment and Services. ... based on an anonymous, independent survey of over 30,000 ...
Breaking Medicine Technology: